NCT01774721 2023-11-14ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.PfizerPhase 3 Completed452 enrolled 35 charts 1 FDA
NCT01000025 2023-08-22PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic CancerCanadian Cancer Trials GroupPhase 3 Completed720 enrolled 14 charts